IBIO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.58%

Insider Buying (Last 12 Months): $74,998.56

Insider Selling (Last 12 Months): $0.00

iBio Insider Trading History Chart

iBio Share Price & Price History

^$0.90

▲ +0.0852 (10.46%)

As of 06/18/2025 05:00 PM ET

Days: 30 | 90 | 365

iBio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/10/2025	David Arkowitz	Director	Buy	18,382	$2.72	$49,999.04	18,382
1/10/2025	Felipe Duran	CFO	Buy	9,191	$2.72	$24,999.52	11,139

SEC Filings (Institutional Ownership Changes) for iBio (NYSE:IBIO)

7.90% of iBio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

iBio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/15/2025	Cubist Systematic Strategies LLC	55,600	$0.22M	0.0%	N/A	0.337%
4/30/2025	Iridian Asset Management LLC CT	58,205	$0.23M	0.1%	N/A	0.589%
2/13/2025	ADAR1 Capital Management LLC	415,606	$1.02M	0.2%	-12.7%	4.228%
2/12/2025	Geode Capital Management LLC	83,797	$0.21M	0.0%	+52.3%	0.852%
8/15/2024	Lynx1 Capital Management LP	240,763	$0.51M	0.2%	-59.9%	2.792%
5/30/2024	Lynx1 Capital Management LP	600,000	$2.44M	0.6%	N/A	6.957%
5/29/2024	Opaleye Management Inc.	680,000	$2.76M	0.6%	N/A	7.889%
5/17/2024	Ikarian Capital LLC	600,000	$2.44M	0.3%	N/A	6.961%

Data available starting January 2016

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Today's Range

Now: $0.90

$0.82

$0.99

50 Day Range

MA: $0.90

$0.70

$1.28

52 Week Range

Now: $0.90

$0.64

$6.89

Volume

887,372 shs

Average Volume

843,297 shs

Market Capitalization

$14.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

Who are the company insiders with the largest holdings of iBio?: iBio's top insider shareholders include:
David Arkowitz (Director)
Felipe Duran (CFO)
Learn More about top insider investors at iBio.
Who are the major institutional investors of iBio?: iBio's top institutional shareholders include:
Iridian Asset Management LLC CT — 0.59%
Cubist Systematic Strategies LLC — 0.34%
Learn More about top institutional investors of iBio stock.
Which institutional investors are buying iBio stock?: During the previous quarter, IBIO stock was acquired by institutional investors including:
Iridian Asset Management LLC CT
Cubist Systematic Strategies LLC
Within the previous year, these company insiders have bought iBio stock:
David Arkowitz (Director)
Felipe Duran (CFO)
Learn More investors buying iBio stock.